Humacyte Investor Relations Material
Latest events
Q1 2025
Humacyte
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Humacyte Inc
Access all reports
Humacyte Inc. is a clinical-stage biotechnology company developing regenerative medicine products. It focuses on bioengineered human tissues and organs for vascular and other applications. The company’s technology platform is designed to produce off-the-shelf, universally implantable tissues. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.
Latest articles
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
Ticker symbol
HUMA
Country
🇺🇸 United States